Aerami Therapeutics to Present Clinical Data on Dance 501 Inhaled Human Insulin at the 19th Diabetes Technology Meeting

DURHAM, N.C., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Aerami Therapeutics , a clinical-stage company reimagining the treatment of chronic diseases with inhaled therapies, today announced that it will present two posters on its Dance 501 inhaled human insulin product candidate for type 1 and type 2 diabetes, at the 19th Diabetes Technology Meeting taking place on November 14-16, 2019 in North Bethesda, Maryland.